Actively Recruiting
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
Led by Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Updated on 2025-06-06
100
Participants Needed
1
Research Sites
88 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a multicentre, open-label, dose-finding/efficacy-expanding phase Ib/II clinical trial to evaluate the tolerability, safety, pharmacokinetic profile and immunogenicity of SHR-A1811 combination regimen in the treatment of recurrent or metastatic cervical cancer and to preliminarily evaluate the efficacy of SHR-A1811 combination regimen for recurrent or metastatic cervical cancer.
CONDITIONS
Official Title
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female aged 18 to 75 years
- Voluntarily agree to join the study and sign informed consent
- Able to comply with follow-up and study procedures
- Expected survival of at least 12 weeks
- Normal vital organ function
- Female of childbearing potential must have a negative serum HCG test within 7 days before first dose and not be breastfeeding
- Agree to use contraception from consent signing until 7 months after last dose
You will not qualify if you...
- History or presence of other cancers
- Severe bone damage from bone metastases
- Active autoimmune disease or history of autoimmune disease with possible recurrence
- Active tuberculosis
- Poorly controlled or severe cardiovascular disease
- Arteriovenous thrombotic events within 6 months before first dose
- Gastrointestinal obstruction or related symptoms within 6 months before first dose
- Serious infection within 1 month before first dose
- History of immunodeficiency
- Other factors judged by investigator that may affect study results or cause early termination
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China, 100730
Actively Recruiting
Research Team
N
Na An
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here